FDA bypasses public input to speed drug approval rule

What it does

This bill requires the FDA to publish a rule within one year replacing all references to 'animal tests' with 'nonclinical tests' across multiple FDA regulations governing drug and biologic approval. The rule becomes effective immediately without the FDA having to justify the change through normal public comment procedures. The bill also fixes a technical numbering error in an earlier law.

Why we flagged it

The bill's substantive goal—replacing animal-testing language with nonclinical-testing language—is a modernization aligned with prior law (2023 Consolidated Appropriations Act). However, the operative mechanism is a procedural bypass: it exempts the interim final rule from the Administrative Procedure Act's notice-and-comment requirement, allowing immediate implementation without public input.

What the text implies

• The bill does not define what 'nonclinical tests' include or exclude—it relies on a definition added elsewhere in the 2023 law. If that definition is ambiguous or broad, the FDA may have discretion to accept alternative methods (in vitro, computational models, etc.) without further rulemaking, potentially accelerating approval timelines without explicit congressional authorization.
• By making the rule 'immediately effective' without good-cause justification, the bill bypasses the 30-day waiting period normally required after an interim final rule is published. This compresses the window for legal challenge and prevents the public from petitioning for reconsideration before the rule takes effect.
• The bill applies to multiple CFR sections governing investigational new drug (IND) applications, new drug applications (NDAs), biologics license applications (BLAs), and over-the-counter drug approvals. The scope is broad, affecting the entire drug approval pipeline, but the bill does not specify how the FDA should validate alternative nonclinical methods or what standards apply.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill accelerates FDA adoption of non-animal testing methods, which may reduce animal suffering and potentially speed drug development; however, it bypasses normal public notice-and-comment rulemaking, limiting transparency and public input on a significant shift in how drug safety is evaluated. The immediate effectiveness clause removes a safeguard that would normally allow the public to challenge the rule.

Who stands to gain

• pharmaceutical companies (reduced animal testing costs, potentially faster approval timelines)
• contract research organizations (CROs) specializing in alternative testing methods (in vitro, comput
• biotechnology firms developing non-animal testing platforms

Named in the bill

FDA (Food and Drug Administration), HHS (Department of Health and Human Services), Bristol Myers Squibb (BMY), Guardant Health (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ), Consolidated Appropriations Act 2023 (Public Law 117–328), Federal Food, Drug, and Cosmetic Act Section 505, Title 21 Code of Federal Regulations

Where it stands

9 cosponsors: 4 Democrats, 4 Republicans, 1 Independents.

• Feb 3, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Feb 3, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
• Dec 16, 2025 — Reported out of committee · Congress.gov: “Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent”
• Dec 16, 2025 — Passed the Senate · Congress.gov: “Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

10 lobbying clients named this bill on 16 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $18,365,234 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 91% of bills with at least one filing.

Cory Booker, the sponsor, reported $496,300 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• Gsk (fka Glaxosmithkline Inc.) — $890,000 on 1 filing
• Fragrance Creators Association — $480,000 on 2 filings
• Consumer Healthcare Products Association — $445,234 on 2 filings
• Public Access to Sunscreens (pass) Coalition — $280,000 on 3 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.